Globus Medical Q4 2023 Adj EPS $0.60 Misses $0.61 Estimate, Sales $616.53M Beat $607.09M Estimate
Portfolio Pulse from Benzinga Newsdesk
Globus Medical (NYSE:GMED) reported Q4 2023 adjusted EPS of $0.60, missing the $0.61 estimate, but sales of $616.53M exceeded the $607.09M estimate. This represents a 1.69% increase in EPS and a 124.60% increase in sales from the same period last year.
February 20, 2024 | 9:40 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Globus Medical's Q4 2023 earnings report showed a slight miss on EPS but a significant beat on sales, with substantial year-over-year growth.
The slight miss in EPS is overshadowed by the significant beat in sales and the impressive year-over-year growth. This mixed result could lead to neutral short-term stock price movement as investors weigh the EPS miss against the strong sales performance.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100